SUNGKYUNKWAN UNIVERSITY
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Private
- Established
- 1398-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.skku.edu
Maternal and Neonatal Outcomes Following Exposure to Benzodiazepines During Pregnancy
Completed
- Conditions
- Pregnancy RelatedBenzodiazepines Causing Adverse Effects in Therapeutic UseCongenital Anomaly
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Sungkyunkwan University
- Target Recruit Count
- 3094227
- Registration Number
- NCT04856436
- Locations
- π°π·
Sungkyunkwan University, Suwon, Gyeonggi-do, Korea, Republic of
Maternal and Fetal Outcomes Following Influenza Vaccination in Pregnancy
- Conditions
- Pregnancy RelatedInfluenza Virus Vaccine Adverse Reaction
- Interventions
- Biological: influenza vaccine
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Sungkyunkwan University
- Target Recruit Count
- 300000
- Registration Number
- NCT04579822
Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
- Conditions
- Pneumococcal Vaccine Adverse Reaction
- Interventions
- Biological: Influenza vaccineBiological: 23-valent pneumococcal polysaccharide vaccineBiological: 10 or 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Sungkyunkwan University
- Target Recruit Count
- 1000000
- Registration Number
- NCT04551248
- Locations
- π°π·
Sungkyunkwan University, Suwon, Gyeonggi-do, Korea, Republic of
A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab
- Conditions
- InfectionRheumatoid Arthritis
- Interventions
- Drug: Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Sungkyunkwan University
- Target Recruit Count
- 9508
- Registration Number
- NCT04115423
- Locations
- π°π·
Sungkyunkwan University, Suwon, Gyeonggi-do, Korea, Republic of
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
- Conditions
- Carcinoma, Non-Small-Cell LungImmune-Related Adverse Events
- Interventions
- Drug: PD-1 inhibitorDrug: Chemotherapy Drugs, Cancer
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Sungkyunkwan University
- Target Recruit Count
- 4724
- Registration Number
- NCT04115410
Β© Copyright 2025. All Rights Reserved by MedPath